Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-37822681
- Development stage
- Phase 2
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JNJ-37822681 is a novel, potent, and highly selective small molecule dopamine D2 receptor antagonist developed as an investigational antipsychotic. It is characterized by fast dissociation from the D2 receptor and high central nervous system specificity with minimal off-target activity at other receptors such as dopamine D1/D3, serotonin 5-HT2A/5-HT2C, adrenergic α1A, histamine H1, and muscarinic receptors. This pharmacological profile was designed to provide antipsychotic efficacy with potentially improved tolerability compared to existing agents. The drug has been studied primarily for the treatment of schizophrenia in phase II clinical trials[1][3][4][8].
- Other names
- 935776-74-23-Pyridazinamine N-(1-((3,4-difluorophenyl)methyl)-4-piperidinyl)-6-(trifluoromethyl)CHEMBL3234237CHEMBL-3234237CHEMBL 3234237
02
Targets
DRD2 (Dopamine D2 Receptor)SIGMAR1 (Sigma non-opioid intracellular receptor 1)
Beyond the preview
Go deeper on JNJ-37822681.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-37822681.